Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

Journal of Hepatology

Volumn 66, Issue 3, 2017, Pages 485-493

  van der Meer, Adriaan J ^a   Feld, Jordan J ^b   Hofer, Harald ^c   Almasio, Piero L ^d   Calvaruso, Vincenza ^d   Fernández Rodríguez, Conrado M ^e   Aleman, Soo ^f   Ganne Carrié, Nathalie ^g   D'Ambrosio, Roberta ^h   Pol, Stanislas ⁱ   Trapero Marugan, Maria ^j   Maan, Raoel ^a   Moreno Otero, Ricardo ^j   Mallet, Vincent ⁱ   Hultcrantz, Rolf ^f   Weiland, Ola ^f   Rutter, Karoline ^c   Di Marco, Vito ^d   Alonso, Sonia ^e   Bruno, Savino ^k   Colombo, Massimo ^h   de Knegt, Robert J ^a   Veldt, Bart J ^a   Hansen, Bettina E ^a   Janssen, Harry L A ^a,b   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF PALERMO   (Italy)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HÔPITAL JEAN VERDIER   (France)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ Università degli Studi di Milano ^*  (France)

^j Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^k HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

more..

Author keywords

Chronic hepatitis C; Cirrhosis; Fibrosis; Hepatocellular carcinoma; Liver failure; Survival analysis; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIBODY; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADULT; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BODY MASS; CANCER RISK; CHRONIC HEPATITIS C; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE COUNT; TRANSIENT ELASTOGRAPHY; VIRAL CLEARANCE; AGED; ANIMAL; CAT; COHORT ANALYSIS; COMPLICATION; DISEASE EXACERBATION; INCIDENCE; LIVER TUMOR; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE;

ADULT; AGED; ANIMALS; CARCINOMA, HEPATOCELLULAR; CATS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SUSTAINED VIROLOGIC RESPONSE;

EID: 85006942581     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.10.017     Document Type: Article

References (52)

1. [1] Fattovich, G., Giustina, G., Degos, F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997), 463–472.
2. [2] Singal, A.G., Volk, M.L., Jensen, D., et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 8 (2010), 280–288.
3. [3] Bruix, J., Sherman, M., Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
4. [4] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55 (2011), 245–264.
5. [5] Davis, G.L., Alter, M.J., El-Serag, H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138 (2010), 513–521.
6. [6] Razavi, H., Waked, I., Sarrazin, C., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21 (2014), 34–59.
7. [7] Vezali, E., Aghemo, A., Colombo, M., A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 32 (2010), 2117–2138.
8. [8] Wedemeyer, H., Duberg, A.S., Buti, M., et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 21 (2014), 60–89.
9. [9] Moyer, V.A., Force USPST. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 159 (2013), 349–357.
10. [10] Smith, B.D., Morgan, R.L., Beckett, G.A., et al. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 157 (2012), 817–822.
11. [11] Aleman, S., Rahbin, N., Weiland, O., et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 57 (2013), 230–236.
12. [12] Bruno, S., Stroffolini, T., Colombo, M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007), 579–587.
13. [13] Cardoso, A.C., Moucari, R., Figueiredo-Mendes, C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 52 (2010), 652–657.
14. [14] Fernandez-Rodriguez, C.M., Alonso, S., Martinez, S.M., et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 105 (2010), 2164–2172.
15. [15] Van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
16. [16] Mashitani, T., Yoshiji, H., Yamazaki, M., et al. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. Cases J, 2, 2009, 18.
17. [17] Aghemo, A., Rumi, M.G., Monico, S., et al. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antivir Ther 14 (2009), 577–584.
18. [18] Braks, R.E., Ganne-Carrie, N., Fontaine, H., et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 13 (2007), 5648–5653.
19. [19] Calvaruso, V., Bavetta, M.G., Ferraro, D., et al. Risk of disease decompensation and HCC in patients with HCV cirrhosis non responders to PEG IFN plus RBV. Hepatology, 56, 2012, 253A.
20. [20] D'Ambrosio, R., Aghemo, A., Grazia Rumi, M., et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56 (2012), 532–543.
21. [21] Mallet, V., Gilgenkrantz, H., Serpaggi, J., et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 149 (2008), 399–403.
22. [22] Rumi, M.G., Aghemo, A., Prati, G.M., et al. Randomized study of peginterferon-alpha2a plus ribavirin vs. peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 138 (2010), 108–115.
23. [23] Rutter, K., Stättermayer, A.F., Ferenci, P., et al. Successful HCV eradication due to antiviral therapy is associated with improved long term outcome of patients with chronic hepatitis C. J Hepatol, 58, 2013, S369.
24. [24] Trapero-Marugan, M., Mendoza, J., Chaparro, M., et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol 17 (2011), 493–498.
25. [25] Bruix, J., Sherman, M., Management of hepatocellular carcinoma. Hepatology 42 (2005), 1208–1236.
26. [26] Veldt, B.J., Chen, W., Heathcote, E.J., et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47 (2008), 1856–1862.
27. [27] Chen, L., Magliano, D.J., Zimmet, P.Z., The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol 8 (2012), 228–236.
28. [28] Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
29. [29] Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
30. [30] Lawitz, E., Gane, E., Pearlman, B., et al. Efficacy and safety of 12 weeks vs. 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2015), 1075–1086.
31. [31] Lawitz, E., Sulkowski, M.S., Ghalib, R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384 (2014), 1756–1765.
32. [32] Poordad, F., Hezode, C., Trinh, R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370 (2014), 1973–1982.
33. [33] Morgan, T.R., Ghany, M.G., Kim, H.Y., et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52 (2010), 833–844.
34. [34] Shiratori, Y., Shiina, S., Teratani, T., et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138 (2003), 299–306.
35. [35] Akamatsu, M., Yoshida, H., Shiina, S., et al. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver Int 26 (2006), 536–542.
36. [36] Rockey, D.C., Caldwell, S.H., Goodman, Z.D., et al. Liver biopsy. Hepatology 49 (2009), 1017–1044.
37. [37] Sewell, J.L., Stick, K.M., Monto, A., Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy. Eur J Gastroenterol Hepatol 21 (2009), 225–229.
38. [38] Chang, K.C., Hung, C.H., Lu, S.N., et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother 67 (2012), 2766–2772.
39. [39] Hirakawa, M., Ikeda, K., Arase, Y., et al. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med 47 (2008), 1637–1643.
40. [40] Ikeda, M., Fujiyama, S., Tanaka, M., et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 40 (2005), 148–156.
41. [41] Iwasaki, Y., Takaguchi, K., Ikeda, H., et al. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 24 (2004), 603–610.
42. [42] Makiyama, A., Itoh, Y., Kasahara, A., et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 101 (2004), 1616–1622.
43. [43] Tokita, H., Fukui, H., Tanaka, A., et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 20 (2005), 752–758.
44. [44] Yamashita, N., Ohho, A., Yamasaki, A., et al. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol 49 (2014), 1504–1513.
45. [45] Arase, Y., Kobayashi, M., Suzuki, F., et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 57 (2013), 964–973.
46. [46] Asahina, Y., Tsuchiya, K., Nishimura, T., et al. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 58 (2013), 1253–1262.
47. [47] Ikeda, K., Marusawa, H., Osaki, Y., et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 146 (2007), 649–656.
48. [48] Liu, Y., Wu, F., Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 118 (2010), 818–824.
49. [49] Pessione, F., Ramond, M.J., Peters, L., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 23 (2003), 45–53.
50. [50] Verrill, C., Markham, H., Templeton, A., et al. Alcohol-related cirrhosis–early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 104 (2009), 768–774.
51. [51] Van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. J Viral Hepat 21 (2014), 568–577.
52. [52] Van der Meer, A.J., Maan, R., de Knegt, R.J., et al. Natural history of HCV-induced liver disease. Curr Hepatitis Rep 12 (2013), 251–260.